PET/CT bests biopsy in diagnosing lymphoma bone marrow involvement

05/17/2013 | MolecularImaging.net

A study published in The Journal of Nuclear Medicine said 18F-FDG-PET/CT is better than the standard bone marrow biopsy in detecting bone marrow involvement in diffuse large B-cell lymphoma. PET/CT identified bone marrow involvement in 32 patients, while biopsy detected bone malignancy in eight patients. PET/CT also showed better performance in terms of sensitivity, predictive value and negative predictive value.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA